MRK.SN
Merck & Co., Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 5,
"returned": 5,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "cfbc08c5-08dc-4e23-ac43-91948050768a",
"title": "Merck Q1: There's Still Room For Growth (NYSE:MRK)",
"description": "Merck's impressive financial performance and cost management suggest continued growth potential. Read what makes MRK stock's attractive valuation worth considering.",
"keywords": "",
"snippet": "JasonDoiy\n\nIntro & Thesis\n\nI initiated coverage of Merck & Co, Inc. (NYSE:MRK) stock in January 2024. Since then, MRK has gained 5.8%, slightly outperforming th...",
"url": "https://seekingalpha.com/article/4689881-merck-q1-theres-still-room-for-growth",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297651436/image_1297651436.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-05-06T21:27:43.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.626408,
"sentiment_score": 0.288143,
"highlights": [
{
"highlight": "JasonDoiy\n\nIntro & Thesis\n\nI initiated coverage of <em>Merck</em> & <em>Co</em>, <em>Inc</em>. (NYSE:MRK) stock in January 2024. Since then, MRK has gained 5.8%, slightly outperforming the S&P 500 (SP500) (SPY) Index.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "In Q1 2024 <em>Merck</em> had an impressive financial performance, with total worldwide sales hitting $15.8 billion - that was a significant 9% YoY increase though slightly lagging behind 2022 results. Excluding FX impacts, this growth surged to an even more remarkable 12%, primarily driven by a robust 10% sales increase in the pharmaceutical division.",
"sentiment": 0.9206,
"highlighted_in": "main_text"
},
{
"highlight": "MRK's IR materials\n\nI particularly like the way <em>Merck</em> managed its costs during the period. Gross margin increased to 77.6% for Q1 FY2024, compared to 72.9% last year, which was primarily attributed to favorable impacts such as product mix, lower royalty rates related to key products like KEYTRUDA and GARDASIL/GARDASIL 9, and FX gains.",
"sentiment": 0.7624,
"highlighted_in": "main_text"
},
{
"highlight": "Second, on May 1, 2024, <em>Merck</em> announced good news about a treatment for advanced stomach or esophageal cancer. In a large study called KEYNOTE-811, a combination of Keytruda (pembrolizumab), trastuzumab, and chemotherapy was investigated.",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "In my opinion, this news indicates that <em>Merck</em> has another chance to solidify its position in the global market for stomach and esophagus cancer, which analysts predict should expand by 10.5% annually (\"CAGR\") to reach a size of $24.1 billion by 2031.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Merck</em> is facing many challenges, particularly due to the loss of exclusivity for important drugs. One example is Remicade, which was co-marketed with Johnson & Johnson (JNJ) many years ago and has to compete with biosimilars in both Europe and the USA.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Merck</em> Q1: There's Still Room For Growth (NYSE:MRK)",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "75a73d6d-de1d-4b32-9d2b-c8557b7c3091",
"title": "NervGen Pharma : Notice of Meeting and Management Proxy Circular",
"description": "NOTICE OF MEETING\n \n \n AND\n \n \n MANAGEMENT PROXY CIRCULAR\n \n \n FOR THE\n \n \n ANNUAL GENERAL MEETING OF SHAREHOLDERS\n ...",
"keywords": "Markets",
"snippet": "NOTICE OF MEETING AND MANAGEMENT PROXY CIRCULAR FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT 1:00 P.M. (PT) ON TUESDAY, JUNE 4, 2024 AT 1133 MEL...",
"url": "https://www.marketscreener.com/quote/stock/NERVGEN-PHARMA-CORP-55763923/news/NervGen-Pharma-Notice-of-Meeting-and-Management-Proxy-Circular-46639761/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-05-06T18:34:06.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.27914,
"sentiment_score": 0.5766,
"highlights": [
{
"highlight": "Thompson served in positions of increasing responsibility at <em>Merck</em> & <em>Co</em>., <em>Inc</em>., including the European partnership with Schering Plough. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and an MBA from the University of Notre Dame. Krista L. McKerracher - Ms.",
"sentiment": 0.5766,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "79ba718b-7aa7-4702-8973-43eda4b36d43",
"title": "CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value (CGON)",
"description": "CG Oncology, Inc. released positive results from cretostimogene study for high-risk BCG-unresponsive bladder cancer patients. Click to see upcoming CGON catalysts.",
"keywords": "",
"snippet": "Nikola Stojadinovic/E+ via Getty Images\n\nCG Oncology, Inc. (NASDAQ:CGON) reported positive results from its phase 3 BOND-003 study, which used its monotherapy i...",
"url": "https://seekingalpha.com/article/4689815-cg-oncology-asco-play-and-top-line-data-end-of-2024-could-drive-further-value",
"image_url": "https://media.gettyimages.com/id/2148013234/photo/medical-coworkers-working-in-a-lab.jpg?b=1&s=170667a&w=0&k=20&c=d3z9ythSnz0oWweC864kgT1GbIrrqlKZbv4vqkCuYZE=",
"language": "en",
"published_at": "2024-05-06T17:04:11.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.616824,
"sentiment_score": 0.6124,
"highlights": [
{
"highlight": "It is important to note that this specific program is being done as a clinical collaboration agreement with <em>Merck</em> & <em>Co</em>., <em>Inc</em>. (MRK). This trial is enrolling a total of 35 patients who are to be treated with cretostimogene + Keytruda over a 12-month period.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b2656331-e24b-4c46-a7bb-d52dd58c7597",
"title": "Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sci",
"description": "The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake, and unhealthy...",
"keywords": "DelveInsight Business Research LLP, Liver Disease Therapeutics, Liver Disease Therapeutics FDA, Liver Disease Therapeutics EMA",
"snippet": "New York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Mar...",
"url": "https://www.globenewswire.com/news-release/2024/05/06/2876066/0/en/Global-Liver-Disease-Therapeutics-Market-to-Grow-Rapidly-by-2030-Examines-DelveInsight-Key-Players-in-the-Market-AbbVie-GSK-F-Hoffmann-La-Roche-Bristol-Myers-Squibb-Company-Abbott-.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
"language": "en",
"published_at": "2024-05-06T17:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.086811,
"sentiment_score": 0.082317,
"highlights": [
{
"highlight": "., <em>Merck</em> & <em>Co</em>., <em>Inc</em>., Alnylam Pharmaceuticals, Inc., Sanofi, GSK plc, and several others, are currently operating in the liver disease therapeutics market.\n\nand several others, are currently operating in the liver disease therapeutics market.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Get a sneak peek at the liver disease therapeutics market dynamics @ Liver Disease Therapeutics Market Dynamics Analysis\n\nReport Metrics Details Coverage Global Study Period 2021–2030 Key Liver Disease Therapeutics Companies AbbVie Inc., GSK, F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Inc., Astellas Pharma Inc., <em>Merck</em>",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Co</em>., <em>Inc</em>., Alnylam Pharmaceuticals, Inc., Sanofi, GSK plc, among others\n\nLiver Disease Therapeutics Market Assessment\n\nLiver Disease Therapeutics Market Segmentation Liver Disease Therapeutics Market Segmentation By Treatment Type: Anti-viral Drugs, Targeted Therapy, Immunosuppressant Drugs, Immunoglobulin, Vaccines, and Others Liver Disease Therapeutics",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, <em>Merck</em> Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, <em>Merck</em> Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "the market trends, market drivers, market barriers, and key NAFLD companies, including MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., <em>Merck</em>",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "c41004e6-6284-4a05-834f-5c01c9e1a941",
"title": "[Latest] Global Cancer Supportive Care Drugs Market Size/Share Worth USD 32,783.2 Billion by 2033 at a 3.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmenta",
"description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cancer Supportive Care...",
"keywords": "CMI MARKET RESEARCH PRIVATE LIMITED, Cancer, Supportive, Care, Drugs, Antiemetics, Erythropoietin, Bisphosphonates, Non-Opioids, Breast, Lung, Prostate, Colorectal, Oral, Injectable, AI",
"snippet": "Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Supportive Care Drugs Market Size,...",
"url": "https://www.globenewswire.com/news-release/2024/05/06/2876054/0/en/Latest-Global-Cancer-Supportive-Care-Drugs-Market-Size-Share-Worth-USD-32-783-2-Billion-by-2033-at-a-3-1-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/74609d89-5437-4826-b7b8-31238ea2e65c",
"language": "en",
"published_at": "2024-05-06T16:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 6.877594,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "Johnson & Johnson\n\n<em>Merck</em> & <em>Co</em>. <em>Inc</em>.\n\nPfizer Inc.\n\nNovartis International AG\n\nBristol Myers Squibb Company\n\nEli Lilly and Company\n\nSanofi S.A.\n\nTakeda Pharmaceutical Company Limited\n\nTeva Pharmaceutical Industries Ltd.\n\nAbbVie Inc.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "MRK.SN",
"total_documents": 5,
"sentiment_avg": 0.2666320040822029
}
]
}
Other details
Exchange
- Santiago Stock Exchange
- equity
- Healthcare
- cl